PortfoliosLab logoPortfoliosLab logo
ESPR vs. SBS
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ESPR vs. SBS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Esperion Therapeutics, Inc. (ESPR) and Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ESPR achieves a -14.86% return, which is significantly lower than SBS's 15.28% return. Over the past 10 years, ESPR has underperformed SBS with an annualized return of -14.95%, while SBS has yielded a comparatively higher 16.43% annualized return.


ESPR

1D
0.00%
1M
0.96%
YTD
-14.86%
6M
-18.18%
1Y
162.50%
3Y*
35.36%
5Y*
-34.62%
10Y*
-14.95%

SBS

1D
-0.18%
1M
-6.98%
YTD
15.28%
6M
14.60%
1Y
38.40%
3Y*
40.12%
5Y*
32.68%
10Y*
16.43%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ESPR vs. SBS - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
ESPR
Esperion Therapeutics, Inc.
-14.86%68.18%-26.42%-52.01%24.60%-80.77%-56.40%29.63%-30.13%425.88%
SBS
Companhia de Saneamento Básico do Estado de São Paulo - SABESP
15.28%80.60%-4.21%46.89%48.42%-13.79%-40.98%91.22%-20.37%23.83%

Correlation

The correlation between ESPR and SBS is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.11

Correlation (3Y)
Calculated over the trailing 3-year period

0.10

Correlation (5Y)
Calculated over the trailing 5-year period

0.11

Correlation (10Y)
Calculated over the trailing 10-year period

0.11

Correlation (All Time)
Calculated using the full available price history since Jun 26, 2013

0.11

Fundamentals

Market Cap

ESPR:

$791.76M

SBS:

$19.24B

EPS

ESPR:

-$0.03

SBS:

R$2.48

PS Ratio

ESPR:

1.75

SBS:

2.48

Total Revenue (TTM)

ESPR:

$418.24M

SBS:

R$38.70B

Gross Profit (TTM)

ESPR:

$226.32M

SBS:

R$13.96B

EBITDA (TTM)

ESPR:

$77.18M

SBS:

R$14.87B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ESPR vs. SBS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ESPR
ESPR Risk / Return Rank: 8686
Overall Rank
ESPR Sharpe Ratio Rank: 8787
Sharpe Ratio Rank
ESPR Sortino Ratio Rank: 8888
Sortino Ratio Rank
ESPR Omega Ratio Rank: 8787
Omega Ratio Rank
ESPR Calmar Ratio Rank: 8484
Calmar Ratio Rank
ESPR Martin Ratio Rank: 8484
Martin Ratio Rank

SBS
SBS Risk / Return Rank: 7373
Overall Rank
SBS Sharpe Ratio Rank: 7777
Sharpe Ratio Rank
SBS Sortino Ratio Rank: 7373
Sortino Ratio Rank
SBS Omega Ratio Rank: 6969
Omega Ratio Rank
SBS Calmar Ratio Rank: 7171
Calmar Ratio Rank
SBS Martin Ratio Rank: 7676
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ESPR vs. SBS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Esperion Therapeutics, Inc. (ESPR) and Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ESPRSBSDifference
Sharpe ratioReturn per unit of total volatility

+0.63

Sortino ratioReturn per unit of downside risk

+1.10

Omega ratioGain probability vs. loss probability

1.36

1.21

+0.15

Calmar ratioReturn relative to maximum drawdown

3.07

1.55

+1.52

Martin ratioReturn relative to average drawdown

7.68

4.65

+3.03

ESPR vs. SBS - Sharpe Ratio Comparison

The current ESPR Sharpe Ratio is 1.76, which is higher than the SBS Sharpe Ratio of 1.14. The chart below compares the historical Sharpe Ratios of ESPR and SBS, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

ESPR vs. SBS - Drawdown Comparison

The maximum ESPR drawdown since its inception was -99.37%, which is greater than SBS's maximum drawdown of -76.49%. Use the drawdown chart below to compare losses from any high point for ESPR and SBS.


Loading charts...

Drawdown Indicators


ESPRSBSDifference

Max Drawdown

Largest peak-to-trough decline

-99.37%

-76.49%

-22.88%

Max Drawdown (1Y)

Largest decline over 1 year

-53.19%

-24.88%

-28.31%

Max Drawdown (3Y)

Largest decline over 3 years

-80.94%

-24.88%

-56.06%

Max Drawdown (5Y)

Largest decline over 5 years

-97.16%

-30.35%

-66.81%

Max Drawdown (10Y)

Largest decline over 10 years

-99.10%

-61.91%

-37.19%

Current Drawdown

Current decline from peak

-97.27%

-22.90%

-74.37%

Average Drawdown

Average peak-to-trough decline

-69.99%

-25.70%

-44.29%

Ulcer Index

Depth and duration of drawdowns from previous peaks

21.30%

8.28%

+13.02%

Volatility

ESPR vs. SBS - Volatility Comparison

The current volatility for Esperion Therapeutics, Inc. (ESPR) is 1.06%, while Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) has a volatility of 8.92%. This indicates that ESPR experiences smaller price fluctuations and is considered to be less risky than SBS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ESPRSBSDifference

Volatility (1M)

Calculated over the trailing 1-month period

1.06%

8.92%

-7.86%

Volatility (6M)

Calculated over the trailing 6-month period

61.44%

24.61%

+36.83%

Volatility (1Y)

Calculated over the trailing 1-year period

92.66%

33.86%

+58.80%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

91.79%

36.90%

+54.89%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

84.61%

43.51%

+41.10%

Dividends

ESPR vs. SBS - Dividend Comparison

ESPR has not paid dividends to shareholders, while SBS's dividend yield for the trailing twelve months is around 2.33%.


PositionTTM20252024202320222021202020192018201720162015
ESPR
Esperion Therapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
SBS
Companhia de Saneamento Básico do Estado de São Paulo - SABESP
2.33%4.68%1.96%1.66%1.88%0.97%2.93%1.99%3.86%2.76%0.65%1.91%

Financials

ESPR vs. SBS - Financials Comparison

This section allows you to compare key financial metrics between Esperion Therapeutics, Inc. and Companhia de Saneamento Básico do Estado de São Paulo - SABESP. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00B10.00B15.00B20222023202420252026
80.10M
9.78B
(ESPR) Total Revenue
(SBS) Total Revenue
Please note, different currencies. ESPR values in USD, SBS values in BRL

ESPR vs. SBS - Profitability Comparison

The chart below illustrates the profitability comparison between Esperion Therapeutics, Inc. and Companhia de Saneamento Básico do Estado de São Paulo - SABESP over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%100.0%202220232024202520260
38.8%
Portfolio components
ESPR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Esperion Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 80.10M. Therefore, the gross margin over that period was 0.0%.

SBS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Companhia de Saneamento Básico do Estado de São Paulo - SABESP reported a gross profit of 3.79B and revenue of 9.78B. Therefore, the gross margin over that period was 38.8%.

ESPR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Esperion Therapeutics, Inc. reported an operating income of -6.58M and revenue of 80.10M, resulting in an operating margin of -8.2%.

SBS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Companhia de Saneamento Básico do Estado de São Paulo - SABESP reported an operating income of 3.33B and revenue of 9.78B, resulting in an operating margin of 34.1%.

ESPR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Esperion Therapeutics, Inc. reported a net income of -25.20M and revenue of 80.10M, resulting in a net margin of -31.5%.

SBS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Companhia de Saneamento Básico do Estado de São Paulo - SABESP reported a net income of 1.72B and revenue of 9.78B, resulting in a net margin of 17.6%.


Frequently Asked Questions


ESPR and SBS have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

SBS has higher volatility (8.92%) compared to ESPR (1.06%). In terms of maximum drawdown, ESPR dropped -99.37% vs SBS's -76.49%.

ESPR currently has the higher Sharpe Ratio (1.76 vs 1.14), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ESPR and SBS

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer